Recent news and earnings call transcripts provide insights into Phibro's Q1 2027 financial performance, dividend declarations, and business commentary.

• Phibro Animal Health reported Q1 2027 earnings with key metrics discussed in earnings call transcripts and related reports, indicating stable financial performance [N1][N2][N3][N4].
• The company declared a quarterly cash dividend of $0.12 per share, reflecting ongoing shareholder returns [N5].
• Recent news coverage includes detailed analysis of Q1 earnings and business outlook commentary from management [N1][N2][N3].

Phibro benefits from global trends such as population growth and expanding middle class driving demand for animal-based proteins, which supports sustained demand for animal health products. The company's acquisition of Zoetis's medicated feed additive portfolio enhances its product breadth and geographic reach. Strong liquidity and credit facilities provide operational flexibility. Continued cybersecurity investments and risk management support operational resilience.

Phibro faces risks from geopolitical conflicts, particularly in the Middle East where it has significant manufacturing operations, which could disrupt supply chains and production. Legal claims and litigation, while currently not expected to materially impact financials, pose ongoing risks. Market and regulatory changes in animal health and mineral nutrition sectors could affect demand. Currency fluctuations and inflationary pressures may impact costs and margins.

Phibro's moat is supported by its diversified global product portfolio in animal health and mineral nutrition, extensive geographic footprint with multiple manufacturing and research facilities, and a broad customer base spanning approximately 90 countries. The acquisition of Zoetis's medicated feed additive portfolio further strengthens its market position and product offerings. The company's established relationships, regulatory approvals, and manufacturing capabilities contribute to barriers to entry for competitors.

• Geopolitical Risks: Ongoing conflicts in the Middle East, especially in Israel where Phibro has manufacturing sites and employees, could disrupt operations, supply chains, and personnel availability [S1].
• Legal and Regulatory Risks: The company faces various claims and litigation related to competition law, labor, consumer protection, data protection, environmental laws, product liability, intellectual property, securities, and contract disputes, which could be costly and affect reputation [S1].
• Market and Industry Risks: Changes in global demand for animal-based proteins, regulatory developments, and competitive pressures in animal health and mineral nutrition markets could impact business performance [S1].
• Financial Risks: Phibro's ability to pay dividends and meet financial obligations depends on operational results, capital requirements, and credit agreements, including the 2024 Credit Agreement and its amendments [S1].
• Cybersecurity Risks: Despite robust cybersecurity measures, evolving cyber threats pose risks to information technology systems and data security [S1].

• Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company developing, manufacturing, and marketing products for food animals such as poultry, beef and dairy cattle, swine, aquaculture, and dogs [S1].
• The company markets approximately 790 product lines in about 90 countries to roughly 4,800 customers [S1].
• Phibro's product portfolio includes animal health and mineral nutrition products, as well as ingredients for personal care, industrial chemical, and chemical catalyst industries [S1].
• In April 2024, Phibro acquired Zoetis Inc.'s medicated feed additive portfolio and related assets for approximately $297.5 million, including six manufacturing sites in the US, Italy, and China. This portfolio generated $407.6 million in revenue in 2023 and contributed $358.2 million and $208.2 million to net sales in fiscal years 2026 and 2025 respectively [S1].
• The acquisition was funded by term loan borrowings under a 2024 Credit Agreement, which was amended in April 2026 to increase revolving credit commitments from $310 million to $435 million, enhancing operating flexibility [S1].
• Phibro operates multiple manufacturing and research facilities globally, including significant sites in Israel, Brazil, the US, China, Italy, Ireland, Argentina, and others, with a detailed list of owned and leased properties [S1].
• The company has approximately 525 employees in Israel, where it operates three manufacturing sites and an office near Tel Aviv. Israeli operations represent 18% of consolidated assets and 16% of consolidated net sales for the twelve months ended June 30, 2026 [S1].
• Phibro maintains a cybersecurity program with managed detection and response services, regular penetration testing, risk assessments, and training programs to mitigate cyber threats [S1].
• The company is subject to various legal claims and litigation arising in the ordinary course of business, including competition law, labor laws, consumer protection, data protection, environmental laws, product liability, intellectual property, securities, breach of contract, and tort claims. Management does not expect these to have a material adverse effect but acknowledges potential risks [S1].
• Phibro's Class A common stock trades on Nasdaq under the symbol PAHC, with 21,068,682 shares outstanding as of June 30, 2026 [S1].
• The company intends to pay regular quarterly dividends subject to board approval and financial condition; a recent quarterly cash dividend declared was $0.12 per share [N5].
• As of September 30, 2026, Phibro reported cash and cash equivalents of $75.5 million, short-term investments of $7.6 million, current assets of $945.2 million, and current liabilities of $295.8 million, resulting in a current ratio of 3.2 and a cash ratio of 0.28 [S2].
• Net income for the quarter ended September 30, 2026, was $29.5 million with basic EPS of $0.73 and diluted EPS of $0.72 [S2].
• Recent earnings calls and reports indicate that Q1 2027 earnings matched expectations and the company provided commentary on key metrics and business conditions [N1][N2][N3][N4].
• Phibro's business is influenced by global population growth and expanding middle class driving demand for animal-based proteins, which supports demand for animal health products [S1].
• The company faces risks related to geopolitical conflicts, notably ongoing hostilities in the Middle East affecting Israeli operations, which could disrupt manufacturing, supply chains, and personnel availability [S1].
• Phibro has limited operations in Russia and Ukraine, with sales representing less than 1% of consolidated net sales, and faces risks from sanctions and geopolitical instability [S1].
• The company has a broad geographic footprint with manufacturing, sales, research, and administrative facilities across multiple continents, supporting diversified operations [S1].